CD8A and myeloid sarcoma: In the study by Sabatino et al., MS patients showed a significantly higher frequency of CD20+CD8+ cells specific to pooled myelin antigens (10.1 ± 2.7% vs. 3.3 ± 1.1%, p = 0.01) and MOG181–189 peptide (21.2 ± 7.8% vs. 0%, p = 0.0002) compared to HD, associated with an overall significant increase in myelin-specific memory CD20+CD8+ T cells (53.7 ± 10.3% vs. 27.0 ± 9.7%, p < 0.05) [8].